Journal of Cellular and Molecular Pharmacology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Case Report   
  • J Cell Mol Pharmacol 2023, Vol 7(5): 176

Mitosis Under Siege the Latest Advances in Mitotic Inhibitor Drug Development

Daisuke Nakanishi*
Laboratory of Hygienic Chemistry and Molecular Toxicology, Gifu Pharmaceutical University, Japan
*Corresponding Author : Daisuke Nakanishi, Laboratory of Hygienic Chemistry and Molecular Toxicology, Gifu Pharmaceutical University, Japan, Email: daisuke.nakanishi@gmail.com

Received Date: Oct 01, 2023 / Published Date: Oct 30, 2023

Abstract

This article delves into the forefront of cancer therapeutics, exploring the latest advances in the development of mitotic inhibitors. Mitosis, the pivotal process of cell division, forms the epicenter of cancer proliferation, making it a prime target for innovative drug interventions. We navigate through the diverse landscape of mitotic inhibitors, unraveling their mechanisms and the recent strides in precision medicine, combination therapies, and advanced drug delivery systems. As mitosis faces a relentless siege, this article outlines the promising developments that hold the potential to redefine cancer treatment strategies.

Citation: Nakanishi D (2023) Mitosis Under Siege the Latest Advances in MitoticInhibitor Drug Development. J Cell Mol Pharmacol 7: 176.

Copyright: © 2023 Nakanishi D. This is an open-access article distributed underthe terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.

Top